Investor Relations
Feb 05, 2019
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes MORE >>
Feb 04, 2019
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes MORE >>
Feb 01, 2019
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer MORE >>
Jan 31, 2019
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator MORE >>

Email Alert Subscription

You may automatically receive OPKO Health, Inc. financial information by email. Please enter your preferences for email notifications below and click "Submit".

Unsubscribe from Investor Relations email alerts.

Our email alerts provide automated opt-out methods as well as complete contact information.